

Giuseppe Derosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8891648/publications.pdf>

Version: 2024-02-01

354
papers

10,718
citations

30047

54
h-index

58549

82
g-index

378
all docs

378
docs citations

378
times ranked

12041
citing authors

#	ARTICLE	IF	CITATIONS
1	State of the art paper Sulfonylureas and their use in clinical practice. Archives of Medical Science, 2015, 4, 840-848.	0.4	351
2	Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α -Glucosidase inhibitors and their use in clinical practice. Archives of Medical Science, 2012, 5, 899-906.	0.4	291
3	A role for quercetin in coronavirus disease 2019 (COVID-19). Phytotherapy Research, 2021, 35, 1230-1236.	2.8	193
4	Anti-obesity drugs: a review about their effects and their safety. Expert Opinion on Drug Safety, 2012, 11, 459-471.	1.0	162
5	Effects of a restricted sleep regimen on ambulatory blood pressure monitoring in normotensive subjects. American Journal of Hypertension, 1996, 9, 503-505.	1.0	160
6	Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases. Molecular Diagnosis and Therapy, 2016, 20, 335-345.	1.6	155
7	Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opinion on Biological Therapy, 2012, 12, 1113-1124.	1.4	150
8	Effects of Telmisartan Compared with Eprosartan on Blood Pressure Control, Glucose Metabolism and Lipid Profile in Hypertensive, Type 2 Diabetic Patients: a Randomized, Double-Blind, Placebo-Controlled 12-Month Study. Hypertension Research, 2004, 27, 457-464.	1.5	148
9	Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2016, 111, 394-404.	3.1	138
10	Matrix Metalloproteinase-2 and -9 Levels in Obese Patients. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 219-224.	1.7	137
11	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clinical Therapeutics, 2004, 26, 744-754.	1.1	136
12	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. Journal of Cellular Physiology, 2018, 233, 153-161.	2.0	134
13	Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. European Journal of Clinical Pharmacology, 2002, 58, 177-180.	0.8	120
14	Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. International Journal of General Medicine, 2021, Volume 14, 2807-2816.	0.8	119
15	Influence of losartan and atenolol on memory function in very elderly hypertensive patients. Journal of Human Hypertension, 2003, 17, 781-785.	1.0	117
16	Matrix Metalloproteinase-2, -9, and Tissue Inhibitor of Metalloproteinase-1 in Patients with Hypertension. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 227-231.	1.7	116
17	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. International Journal of General Medicine, 2021, Volume 14, 2359-2366.	0.8	116
18	Evaluation of α 2 and α 9 levels and their inhibitors in diabetic and healthy subjects. Diabetes and Metabolism, 2007, 33, 129-134.	1.4	114

#	ARTICLE	IF	CITATIONS
19	Exenatide Versus Glibenclamide in Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 233-240.	2.4	113
20	Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 721-728.	2.2	113
21	The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2003, 25, 1429-1439.	1.1	108
22	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 887-895.	1.5	102
23	Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. <i>Journal of Human Hypertension</i> , 2007, 21, 220-224.	1.0	96
24	Ellagic Acid and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 928, 473-479.	0.8	87
25	Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study. <i>Inflammation</i> , 2013, 36, 914-920.	1.7	85
26	Metformin+pioglitazone and metformin+rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 375-383.	0.7	84
27	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 475-482.	1.4	84
28	Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , 2002, 15, 1042-1049.	1.0	83
29	Exosomes: Nanoparticulate tools for RNA interference and drug delivery. <i>Journal of Cellular Physiology</i> , 2017, 232, 1660-1668.	2.0	82
30	Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. <i>Clinical Therapeutics</i> , 2004, 26, 1228-1236.	1.1	79
31	Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. <i>Clinical Therapeutics</i> , 2004, 26, 1599-1607.	1.1	77
32	A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , 2005, 69, 5-13.	1.1	77
33	Telmisartan and Irbesartan Therapy in Type 2 Diabetic Patients Treated with Rosiglitazone: Effects on Insulin-Resistance, Leptin and Tumor Necrosis Factor- α . <i>Hypertension Research</i> , 2006, 29, 849-856.	1.5	77
34	Piperine and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 928, 173-184.	0.8	76
35	Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. <i>Clinical Therapeutics</i> , 2003, 25, 472-484.	1.1	72
36	Different Effect of Psyllium and Guar Dietary Supplementation on Blood Pressure Control in Hypertensive Overweight Patients: A Six-Month, Randomized Clinical Trial. <i>Clinical and Experimental Hypertension</i> , 2007, 29, 383-394.	0.5	72

#	ARTICLE	IF	CITATIONS
37	Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. <i>American Journal of Hypertension</i> , 2002, 15, 316-320.	1.0	69
38	Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 261-268.	0.7	69
39	Effect of Valsartan and Ramipril on Atrial Fibrillation Recurrence and P-wave dispersion in Hypertensive Patients With Recurrent Symptomatic Lone Atrial Fibrillation. <i>American Journal of Hypertension</i> , 2008, 21, 1034-1039.	1.0	69
40	Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. <i>Clinical Therapeutics</i> , 2003, 25, 1107-1122.	1.1	68
41	Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial. <i>Clinical Therapeutics</i> , 2006, 28, 679-688.	1.1	66
42	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	66
43	Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. <i>Nutrition Research</i> , 2013, 33, 622-628.	1.3	65
44	Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2010, 70, 1945-1961.	4.9	64
45	Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. <i>European Journal of Pharmacology</i> , 2011, 666, 251-256.	1.7	64
46	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β -cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 51-60.	1.1	64
47	Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. <i>Diabetes, Obesity and Metabolism</i> , 2005, 7, 47-55.	2.2	63
48	Peroxisome Proliferator-Activated Receptor- γ (PPAR- γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk. <i>Current Molecular Pharmacology</i> , 2012, 5, 272-281.	0.7	63
49	State of the art papers Dietary and nutraceutical approach to type 2 diabetes. <i>Archives of Medical Science</i> , 2014, 2, 336-344.	0.4	62
50	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010, 3, 47-54.	0.2	60
51	Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 102, 63-70.	3.1	60
52	Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 350-364.	2.4	58
53	Exenatide plus metformin compared with metformin alone on β -cell function in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 1515-1523.	1.2	58
54	Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review. <i>Clinical Therapeutics</i> , 2012, 34, 1221-1236.	1.1	58

#	ARTICLE	IF	CITATIONS
55	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , 2007, 22, 361-370.	0.5	57
56	Blood Pressure Control and Inflammatory Markers in Type 2 Diabetic Patients Treated with Pioglitazone or Rosiglitazone and Metformin. <i>Hypertension Research</i> , 2007, 30, 387-394.	1.5	56
57	What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. <i>Acta Diabetologica</i> , 2004, 41, 91-98.	1.2	55
58	A Clinical Trial about a Food Supplement Containing $\hat{\pm}$ -Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1802.	1.8	55
59	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2016, 374, 1094-1096.	13.9	55
60	Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. <i>Current Pharmaceutical Design</i> , 2018, 24, 123-129.	0.9	54
61	Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. <i>Diabetes Research and Clinical Practice</i> , 2003, 60, 161-169.	1.1	52
62	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: Evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , 2012, 6, 553-564.	0.6	52
63	Comparison of the Effects of Valsartan and Felodipine on Plasma Leptin and Insulin Sensitivity in Hypertensive Obese Patients. <i>Hypertension Research</i> , 2005, 28, 209-214.	1.5	51
64	Omega 3 Polyunsaturated Fatty Acids Supplementation and Blood Pressure Levels in Hypertriglyceridemic Patients with Untreated Normal-High Blood Pressure and With or Without Metabolic Syndrome: A Retrospective Study. <i>Clinical and Experimental Hypertension</i> , 2010, 32, 137-144.	0.5	51
65	GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy. <i>Current Clinical Pharmacology</i> , 2012, 7, 214-228.	0.2	51
66	Effects of statin therapy on augmentation index as a measure of arterial stiffness: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2016, 212, 160-168.	0.8	51
67	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , 2017, 400, 325-335.	3.2	51
68	Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients. <i>Hormone and Metabolic Research</i> , 2010, 42, 663-669.	0.7	50
69	<i>Berberis aristata</i> / <i>Silybum marianum</i> fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1495-1506.	1.4	50
70	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010, 57, 777-786.	0.7	48
71	Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride. <i>Hypertension Research</i> , 2005, 28, 917-924.	1.5	47
72	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011, 651, 240-250.	1.7	47

#	ARTICLE	IF	CITATIONS
73	Vildagliptin Added to Metformin on β -Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 475-484.	2.4	47
74	Effects of ω 3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , 2016, 42, 316-322.	2.6	47
75	Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2016, 76, 947-956.	4.9	46
76	Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. <i>Autoimmunity Reviews</i> , 2016, 15, 344-353.	2.5	46
77	Alkaloids in the Nature: Pharmacological Applications in Clinical Practice of Berberine and Mate Tea. <i>Current Topics in Medicinal Chemistry</i> , 2013, 14, 200-206.	1.0	45
78	Effect of Telmisartan+Amlodipine Combination at Different Doses on Urinary Albumin Excretion in Hypertensive Diabetic Patients With Microalbuminuria. <i>American Journal of Hypertension</i> , 2007, 20, 417-422.	1.0	44
79	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1091-1099.	2.2	44
80	Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. <i>Internal Medicine Journal</i> , 2007, 37, 79-86.	0.5	43
81	Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 187-195.	0.7	42
82	Effect of amlodipine+atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. <i>American Journal of Hypertension</i> , 2004, 17, 823-827.	1.0	41
83	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009, 24, 204-210.	0.5	41
84	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , 2018, 42, 75-82.	2.3	40
85	Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 817-822.	0.8	39
86	Comparative Evaluation of Effect of Valsartan/Amlodipine and Atenolol/Amlodipine Combinations on Atrial Fibrillation Recurrence in Hypertensive Patients With Type 2 Diabetes Mellitus. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 51, 217-222.	0.8	39
87	Oral Glucose Tolerance Test Effects on Endothelial Inflammation Markers in Healthy Subjects and Diabetic Patients. <i>Hormone and Metabolic Research</i> , 2010, 42, 8-13.	0.7	39
88	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 164-171.	0.8	39
89	Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 807-818.	1.1	39
90	Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2006, 8, 197-205.	2.2	38

#	ARTICLE	IF	CITATIONS
91	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 607-615.	0.9	38
92	Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: A 12-month, double-blind, randomized clinical trial. <i>Clinical Therapeutics</i> , 2005, 27, 1383-1391.	1.1	37
93	Vascular Remodeling and Prothrombotic Markers in Subjects Affected by Familial Combined Hyperlipidemia and/or Metabolic Syndrome in Primary Prevention for Cardiovascular Disease. Endothelium: Journal of Endothelial Cell Research, 2007, 14, 193-198.	1.7	37
94	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1973-1983.	0.9	37
95	A systematic review and meta-analysis of randomized controlled trials investigating the effects of supplementation with <i>Nigella sativa</i> (black seed) on blood pressure. <i>Journal of Hypertension</i> , 2016, 34, 2127-2135.	0.3	37
96	Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 596-599.	1.0	36
97	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011, 34, 145-151.	1.5	36
98	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009, 32, 124.	0.3	36
99	EFFECTS OF SIBERIAN GINSENG (ELEUTHEROCOCCUS SENTICOSUS MAXIM.) ON ELDERLY QUALITY OF LIFE: A RANDOMIZED CLINICAL TRIAL. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 69-73.	1.4	35
100	Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2005, 70, 119-125.	1.1	34
101	Comparative Effects of Telmisartan and Eprosartan on Insulin Sensitivity in the Treatment of Overweight Hypertensive Patients. <i>Hormone and Metabolic Research</i> , 2009, 41, 893-898.	0.7	34
102	Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients. <i>Internal Medicine</i> , 2010, 49, 1717-1725.	0.3	34
103	Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 421-429.	1.5	34
104	ORIGINAL ARTICLE: Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 565-579.	0.7	33
105	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , 2015, 239, 87-92.	0.4	33
106	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1971-1982.	0.9	32
107	Effects of Thiazolidinediones and Sulfonylureas in Patients with Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 491-501.	2.4	32
108	Metalloproteinase-2 and -9 in Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007, 14, 45-51.	1.7	31

#	ARTICLE	IF	CITATIONS
109	A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2003, 25, 2006-2021.	1.1	30
110	Effect of Delapril/Manidipine vs Olmesartan/ Hydrochlorothiazide Combination on Insulin Sensitivity and Fibrinogen in Obese Hypertensive Patients. <i>Internal Medicine</i> , 2008, 47, 361-366.	0.3	30
111	Efficacy and safety of two treatment combinations of hypertension in very elderly patients. <i>Archives of Gerontology and Geriatrics</i> , 2009, 48, 401-405.	1.4	30
112	Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. <i>Hypertension Research</i> , 2010, 33, 236-242.	1.5	30
113	Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 642-651.	1.0	30
114	Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load. <i>Hormone and Metabolic Research</i> , 2011, 43, 505-512.	0.7	30
115	Variations in Inflammatory Biomarkers Following the Addition of Sitagliptin in Patients with Type 2 Diabetes not Controlled with Metformin. <i>Internal Medicine</i> , 2013, 52, 2179-2187.	0.3	30
116	Effects of long chain n-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1239-1247.	0.9	29
117	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010, 80, 110-115.	1.1	29
118	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 329-335.	1.1	29
119	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , 2016, 35, 1091-1095.	2.3	29
120	Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. <i>Diabetes, Nutrition & Metabolism</i> , 2004, 17, 222-9.	0.4	29
121	Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2005, 45, 599-604.	0.8	28
122	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 957-967.	1.5	28
123	Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1481-1488.	2.0	28
124	Optimizing combination treatment in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2007, 3, 665-71.	1.0	28
125	Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. <i>Journal of Human Hypertension</i> , 2004, 18, 687-691.	1.0	27
126	Effect of Telmisartan on Paroxysmal Atrial Fibrillation Recurrence in Hypertensive Patients With Normal or Increased Left Atrial Size. <i>Clinical Cardiology</i> , 2012, 35, 359-364.	0.7	27

#	ARTICLE	IF	CITATIONS
127	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 221-229.	1.0	27
128	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markers in the progression of diabetes in obese patients (The RESISTIN trial). <i>Cytokine</i> , 2020, 127, 154947.	1.4	27
129	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 907-914.	1.1	27
130	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010, 33, 790-795.	1.5	26
131	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011, 113, 950-960.	1.0	26
132	Effect of Telmisartan and Ramipril on Atrial Fibrillation Recurrence and Severity in Hypertensive Patients With Metabolic Syndrome and Recurrent Symptomatic Paroxysmal and Persistent Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 34-43.	1.0	26
133	Improvement of plasma adiponectin, leptin and C-reactive protein concentrations by orlistat: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 819-834.	1.1	26
134	Long-term Effect of Glimepiride and Rosiglitazone on Non-conventional Cardiovascular Risk Factors in Metformin-treated Patients Affected by Metabolic Syndrome: A Randomized, Double-blind Clinical Trial. <i>Journal of International Medical Research</i> , 2005, 33, 284-294.	0.4	25
135	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , 2010, 33, 209-213.	1.5	25
136	Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2011, 4, 263.	1.1	25
137	Berberis aristata/Silybum marianum fixed combination (Berberol [®]) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , 2015, 22, 231-237.	2.3	25
138	Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q ₁₀ on lipid levels: a randomized, double-blind, placebo controlled study. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1585-1592.	2.0	25
139	Quercetin Phytosome [®] as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.3	25
140	Different Effects of Aliskiren and Losartan on Fibrinolysis and Insulin Sensitivity in Hypertensive Patients with Metabolic Syndrome. <i>Hormone and Metabolic Research</i> , 2010, 42, 892-896.	0.7	24
141	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010, 79, 144-149.	1.1	24
142	Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. <i>Hypertension Research</i> , 2011, 34, 1321-1326.	1.5	24
143	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2581-2591.	0.9	24
144	Variation in Inflammatory Markers and Glycemic Parameters After 12 Months of Exenatide Plus Metformin Treatment Compared with Metformin Alone: A Randomized Placebo-Controlled Trial. <i>Pharmacotherapy</i> , 2013, 33, 817-826.	1.2	24

#	ARTICLE	IF	CITATIONS
145	Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus. <i>Hypertension Research</i> , 2008, 31, 43-50.	1.5	23
146	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2011, 91, 265-270.	1.1	23
147	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , 2020, 73, 110700.	1.1	23
148	Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. <i>Diabetes, Nutrition & Metabolism</i> , 2004, 17, 143-50.	0.4	23
149	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2007, 29, 602-610.	1.1	22
150	Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 267-276.	0.7	22
151	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1059-1066.	1.5	22
152	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β -cell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2433-2442.	0.9	22
153	A review about biomarkers for the investigation of vascular function and impairment in diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 415-419.	1.0	22
154	Curcuminoids Lower Plasma Leptin Concentrations: A Meta-analysis. <i>Phytotherapy Research</i> , 2017, 31, 1836-1841.	2.8	22
155	Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. <i>Biomedicine and Pharmacotherapy</i> , 2005, 59, 312-317.	2.5	21
156	Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 393-403.	1.3	21
157	Continuous Glucose Monitoring System in Free-Living Healthy Subjects: Results from a Pilot Study. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 159-169.	2.4	21
158	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 723-733.	2.5	21
159	<p>Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3647-3655.	2.0	21
160	Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: A possible role for the coenzyme Q10?. <i>BioFactors</i> , 2005, 23, 7-14.	2.6	20
161	Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardio-vascular Disease: Response to Beishuizen et al.. <i>Diabetes Care</i> , 2005, 28, 1262-1263.	4.3	20
162	Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. <i>Journal of International Medical Research</i> , 2006, 34, 545-555.	0.4	20

#	ARTICLE	IF	CITATIONS
163	Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naïve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial. <i>Internal Medicine</i> , 2007, 46, 1837-1846.	0.3	20
164	Effect of Valsartan Addition to Amlodipine on Insulin Sensitivity in Overweight-Obese Hypertensive Patients. <i>Internal Medicine</i> , 2008, 47, 1851-1857.	0.3	20
165	Drug safety evaluation of amlodipine. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 795-804.	1.0	20
166	Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. <i>Diabetic Medicine</i> , 2012, 29, 24-31.	1.2	20
167	<p>An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 653-661.	1.1	20
168	Antithrombotic Effects of Rosiglitazone-Metformin versus Glimepiride-Metformin Combination Therapy in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. <i>Pharmacotherapy</i> , 2005, 25, 637-645.	1.2	19
169	Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. <i>Advances in Therapy</i> , 2006, 23, 680-695.	1.3	19
170	Rosiglitazone Therapy Improves Insulin Resistance Parameters in Overweight and Obese Diabetic Patients Intolerant To Metformin. <i>Archives of Medical Research</i> , 2008, 39, 412-419.	1.5	19
171	Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 724-732.	0.7	19
172	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2017, 18, 343.	1.8	19
173	Matrix Metalloproteinase 2 May Be a Marker of Microangiopathy in Children and Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2004, 27, 273-274.	4.3	18
174	Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. <i>Current Medical Research and Opinion</i> , 2012, 28, 1435-1445.	0.9	18
175	Quercetin Phytosome® as a potential candidate for managing COVID-19. <i>Minerva Gastroenterology</i> , 2021, 67, 190-195.	0.3	18
176	Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009, 34, 13-23.	0.7	17
177	A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 214-222.	2.4	17
178	Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: A 12-years follow-up of the Brisighella Heart Study historical cohort. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 183-188.	1.1	17
179	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , 2015, 100, 127-134.	3.1	17
180	Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study. <i>Journal of Medicinal Food</i> , 2015, 18, 1270-1273.	0.8	17

#	ARTICLE	IF	CITATIONS
181	Auraptene and Its Role in Chronic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 929, 399-407.	0.8	17
182	Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial. <i>Current Therapeutic Research</i> , 2002, 63, 621-633.	0.5	16
183	IFN- γ Low Production Capacity in Type 1 Diabetes Mellitus Patients at Onset of Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2005, 113, 313-317.	0.6	16
184	Red Yeast Rice and Statin-Intolerant Patients. <i>American Journal of Cardiology</i> , 2010, 105, 1504.	0.7	16
185	Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. <i>Hypertension Research</i> , 2011, 34, 509-515.	1.5	16
186	<i>Ascophyllum nodosum</i> and <i>Fucus vesiculosus</i> on glycemic status and on endothelial damage markers in dysglycemic patients. <i>Phytotherapy Research</i> , 2019, 33, 791-797.	2.8	16
187	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , 2021, 8, 605691.	1.2	16
188	Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. <i>Current Therapeutic Research</i> , 2002, 63, 1-14.	0.5	15
189	Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors. <i>Current Clinical Pharmacology</i> , 2008, 3, 77-84.	0.2	15
190	Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 835-843.	0.6	15
191	Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1351-1358.	0.9	15
192	Effects of canrenone in patients with metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2161-2169.	0.9	15
193	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1113-1122.	0.8	15
194	Relationship Between Serum Uric Acid and Electrocardiographic Alterations in a Large Sample of General Population: Data From the Brisighella Heart Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 129-134.	1.0	15
195	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 66.	0.7	15
196	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 328-335.	5.4	15
197	Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of the Cremona Population Study. <i>Atherosclerosis</i> , 1998, 140, 65-70.	0.4	14
198	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1552-1557.	1.5	14

#	ARTICLE	IF	CITATIONS
199	Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 698-704.	3.1	14
200	Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. <i>Advances in Therapy</i> , 2010, 27, 48-55.	1.3	14
201	Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2441-2448.	0.9	14
202	Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1380-1396.	1.1	14
203	High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3425-3434.	2.0	14
204	Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2013, 27, 717-28.	0.7	14
205	Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control in Patients with Impaired Glucose Tolerance. <i>Clinical Drug Investigation</i> , 2006, 26, 529-539.	1.1	13
206	Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 139-144.	1.0	13
207	Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study. <i>Current Therapeutic Research</i> , 2008, 69, 1-15.	0.5	13
208	Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1875-1884.	0.9	13
209	Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 277-285.	0.7	13
210	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , 2015, 38, 690-694.	1.5	13
211	Metalloproteinases in Diabetics and Nondiabetics during Acute Coronary Syndromes and after 3 Months. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007, 14, 175-183.	1.7	12
212	Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine. <i>Internal Medicine</i> , 2009, 48, 265-271.	0.3	12
213	Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 341-347.	2.2	12
214	A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β -cell function: the triple oral therapy. <i>Diabetic Medicine</i> , 2013, 30, 846-854.	1.2	12
215	Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 453-459.	0.9	12
216	<p>Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients<p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1861-1865.	1.1	12

#	ARTICLE	IF	CITATIONS
217	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 845-859.	0.6	12
218	A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2014, 28, 317-24.	0.7	12
219	Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010, 13, 378.	0.9	11
220	Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2011, 36, 592-601.	0.7	11
221	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012, 59, 611-619.	0.7	11
222	Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. <i>Atherosclerosis</i> , 2014, 235, 81-83.	0.4	11
223	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , 2015, 766, 31-36.	1.7	11
224	Abcsic Acid Treatment in Patients with Prediabetes. <i>Nutrients</i> , 2020, 12, 2931.	1.7	11
225	<sc> </sc>, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , 2020, 34, 1377-1384.	2.8	11
226	Effect of Sibutramine on Plasma C-Reactive Protein, Leptin and Adipon ectin Concentrations: A Systematic Review and Meta-Analysis of Randomized Contr olled Trials. <i>Current Pharmaceutical Design</i> , 2017, 23, 870-878.	0.9	11
227	Effects of Insulin Therapy with Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Patients: Comparison with Multi-daily Insulin Injections Therapy (MDI). <i>Endocrine Journal</i> , 2009, 56, 571-578.	0.7	10
228	Pioglitazone is a Valid Alternative to Rosiglitazone. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 357-362.	1.0	10
229	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1091-1099.	0.9	10
230	Effect of Doxazosin on C-Reactive Protein Plasma Levels and on Nitric Oxide in Patients With Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 508-512.	0.8	9
231	Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 629-636.	0.9	9
232	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015, 14, 95.	2.7	9
233	Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 297-304.	1.2	9
234	Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1637-1640.	0.9	9

#	ARTICLE	IF	CITATIONS
235	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1391-1399.	1.0	9
236	<p>Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5367-5374.	2.0	9
237	Pioglitazone plus glimepiride: a promising alternative in metabolic control. <i>International Journal of Clinical Practice</i> , 2007, 61, 28-36.	0.8	8
238	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , 2009, 18, 111-116.	0.7	8
239	Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine. <i>Vascular Health and Risk Management</i> , 2010, 6, 87.	1.0	8
240	Time to Achieve Blood Pressure Goal with a Combination Versus a Conventional Monotherapy Approach in Hypertensive Patients with Metabolic Syndrome. <i>Clinical and Experimental Hypertension</i> , 2010, 32, 245-250.	0.5	8
241	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , 2015, 47, 47-52.	1.5	8
242	Glucoseâ€lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 554-559.	2.2	8
243	Retargeting the management of hypercholesterolemia – focus on evolocumab. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1365-1376.	0.9	8
244	Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies. <i>Medicine (United States)</i> , 2016, 95, e3084.	0.4	8
245	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 582556.	2.2	8
246	Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients. <i>Journal of Human Hypertension</i> , 2003, 17, 433-435.	1.0	7
247	Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1499-1503.	0.6	7
248	Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients. <i>Clinical and Experimental Hypertension</i> , 2013, 35, 301-307.	0.5	7
249	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 621-629.	1.0	7
250	Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. <i>Archives of Medical Science</i> , 2013, 2, 238-242.	0.4	7
251	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placeboâ€Controlled Trial. <i>Pharmacotherapy</i> , 2015, 35, 983-990.	1.2	7
252	Efficacy and safety of two dosages of canrenone as addâ€on therapy in hypertensive patients taking aceâ€inhibitors or angiotensin <sc>II</sc> receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The <sc>ESCAPE</sc>â€<sc>IT</sc> trial. <i>Cardiovascular Therapeutics</i> , 2017, 35, 47-54.	1.1	7

#	ARTICLE	IF	CITATIONS
253	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 572.	1.8	7
254	Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV. <i>Diabetes Therapy</i> , 2021, 12, 1279-1297.	1.2	7
255	Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2009, 7, 120-136.	0.8	6
256	Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. <i>Integrated Blood Pressure Control</i> , 2010, 3, 21.	0.4	6
257	Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 409-414.	1.0	6
258	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , 2017, 92, 75-79.	1.4	6
259	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , 2018, 233, 1791-1795.	2.0	6
260	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2611-2616.	2.0	6
261	Glycemic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3219.	1.7	6
262	Prospects for the development of novel anti-hyperlipidemic drugs. <i>Current Opinion in Investigational Drugs</i> , 2006, 7, 826-33.	2.3	6
263	Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials. <i>Current Clinical Pharmacology</i> , 2006, 1, 21-33.	0.2	5
264	Assessment and management of left ventricular hypertrophy in Type 2 diabetes patients with high blood pressure. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 719-728.	0.6	5
265	Hypoglycemia, its implications in clinical practice, and possible ways to prevent it. <i>Current Medical Research and Opinion</i> , 2014, 30, 771-773.	0.9	5
266	Are there mild and serious metabolic syndromes? The need for a graded diagnosis. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 759-760.	0.6	5
267	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , 2020, , 1-10.	0.6	5
268	PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa180.	0.1	5
269	Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study. <i>Biomedicines</i> , 2022, 10, 656.	1.4	5
270	Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. <i>Current Therapeutic Research</i> , 2002, 63, 216-226.	0.5	4

#	ARTICLE	IF	CITATIONS
271	Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 371-384.	0.9	4
272	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , 2015, 5, 12603.	1.6	4
273	Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?. <i>Current Vascular Pharmacology</i> , 2016, 14, 321-322.	0.8	4
274	Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2293-2300.	2.0	4
275	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , 2019, 11, 3075.	1.7	4
276	Canrenone on cardiovascular mortality in congestive heart failure. <i>Pharmacological Research</i> , 2019, 141, 46-52.	3.1	4
277	Galectin-3 Plasma Levels Are Associated with Risk Profiles in Pulmonary Arterial Hypertension. <i>Diagnostics</i> , 2020, 10, 857.	1.3	4
278	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 191-195.	0.7	4
279	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, <i>Vitis vinifera</i> L. and <i>Ginkgo biloba</i> , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction. <i>Frontiers in Endocrinology</i> , 2022, 13, 847240.	1.5	4
280	Effect of oral chronic isoavones supplementation on male rat sexual performances and sexual hormone plasma levels. <i>Phytotherapy Research</i> , 2004, 18, 849-852.	2.8	3
281	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2008, 1, 33-36.	0.2	3
282	Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2463-2473.	0.9	3
283	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1136-1141.	1.2	3
284	Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, .	0.6	3
285	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2008, 2, 189-98.	4.7	3
286	Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus. <i>Drugs and Therapy Perspectives</i> , 2006, 22, 1-6.	0.3	2
287	Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006, 13, 47-52.	1.0	2
288	A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2008, 1, 33-36.	0.2	2

#	ARTICLE	IF	CITATIONS
289	Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2016.	0.1	2
290	Difference in incidence of cough induced by imidapril and ramipril: Role of prostaglandin synthesis inhibition. <i>Biomedicine and Aging Pathology</i> , 2011, 1, 73-77.	0.8	2
291	LONG-TERM EFFECTS OF A BERBERINE BASED NUTRACEUTICAL ON BODY WEIGHT AND INSULIN-SENSITIVITY IN NON DIABETIC HYPERLIPIDAEMIC PATIENTS. <i>Journal of Hypertension</i> , 2011, 29, e160.	0.3	2
292	Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors. <i>Evidence-Based Medicine</i> , 2011, 16, 7-8.	0.6	2
293	Sitagliptin: results from clinical practice. <i>Current Medical Research and Opinion</i> , 2013, 29, 1483-1485.	0.9	2
294	Management of type 2 diabetes mellitus in chronic kidney disease. <i>Current Medical Research and Opinion</i> , 2015, 31, 95-97.	0.9	2
295	EXAMINE: targeting risk and treatment in diabetes. <i>Lancet, The</i> , 2015, 386, 1443.	6.3	2
296	Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. <i>Exposure and Health</i> , 2016, , 1-11.	2.8	2
297	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , 2017, 14, 760-765.	0.4	2
298	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2%) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Dysglycemia: A Randomized Trial. <i>Life</i> , 2021, 11, 709.	1.1	2
299	Overview of Biochemical Markers of Bone Metabolism. <i>Biomarkers in Disease</i> , 2017, , 3-21.	0.0	2
300	P2975 Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: a 5-year follow-up study. <i>European Heart Journal</i> , 2003, 24, 577.	1.0	2
301	Effects of a nutraceutical combination of monacolin, $\hat{1}^3$ -oryzanol and $\hat{1}^3$ -aminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , 2019, 15, 792-796.	0.4	2
302	Evaluation in Patients with High NORMAL Blood Pressure of a Supplement Containing Arginine, Lactobacillus Plantarum Lp-LDL, Coenzyme Q10 and Vitamin B1: A PILOT Study. <i>Journal of Food and Nutrition Research (Newark, Del)</i> , 2020, 8, 273-278.	0.1	2
303	Evaluation of the Effects of a Supplement Composed by Quercetin, Rutin, Bromelain and L-Carnosine in Patients with Borderline Uricemia. <i>Journal of Food and Nutrition Research (Newark, Del)</i> , 2020, 8, 550-555.	0.1	2
304	Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. <i>American Journal of Hypertension</i> , 2002, 15, A35.	1.0	1
305	Association between Lowâ€Molecular Weight Apolipoprotein(a) Isoforms and Obesity in Italian Women. <i>Obesity</i> , 2004, 12, 1322-1326.	4.0	1
306	Effect of valsartan on adiponectine, leptin and resistin in hypertensive obese patients. <i>American Journal of Hypertension</i> , 2005, 18, A196-A197.	1.0	1

#	ARTICLE	IF	CITATIONS
307	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2007, .	4.7	1
308	25 LONG-TERM EFFECTIVENESS AND SAFETY OF A NUTRACEUTICAL BASED APPROACH TO REDUCE CHOLESTEROLEMIA IN STATIN INTOLERANT SUBJECTS WITH AND WITHOUT METABOLIC SYNDROME. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, S41.	1.1	1
309	11.11 Effect of Valsartan-Amlodipine Combination on Cognitive Function In Elderly Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 307-307.	1.0	1
310	20 LOSARTAN ALONE OR COMBINED WITH SIMVASTATIN IMPROVED VISCERAL ADIPOSE TISSUE AND INFLAMMATION IN HYPERTENSIVE NORMOCHOLESTEROLEMIC PATIENTS WITH NON-ALCOHOLIC HEPATIC STEATOSIS. <i>Journal of Hepatology</i> , 2011, 54, S9-S10.	1.8	1
311	Letter to the Editor A curious case of hypoglycaemia. <i>Archives of Medical Science</i> , 2013, 4, 752-754.	0.4	1
312	Glibenclamide and cardio-metabolic risk: a systematic review. <i>International Journal of Diabetes in Developing Countries</i> , 2014, 34, 61-68.	0.3	1
313	Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on well-being and sexual performance in patients with perceived worsening of erectile function during statin treatment: a randomised clinical trial. <i>Nutrafoods</i> , 2015, 14, 127-131.	0.5	1
314	Inhaled insulin: weighing the pros and cons. <i>Lancet Diabetes and Endocrinology</i> , the, 2015, 3, 834-835.	5.5	1
315	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , 2019, 17, 1087-1092.	0.4	1
316	Traditional Markers in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 3-22.	0.0	1
317	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 693-705.	0.0	1
318	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009, 2, 51.	1.1	1
319	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles. , 2015, , 1-24.		1
320	Lipoprotein (a) Particles Characterization by Dynamic Light Scattering. <i>British Journal of Medicine and Medical Research</i> , 2016, 16, 1-8.	0.2	1
321	Detection of sieric BAG3 in patients affected by cardiovascular diseases: State of art and perspectives. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 54-58.	1.2	1
322	Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. <i>American Journal of Hypertension</i> , 2002, 15, A36.	1.0	0
323	Effect of losartan irbesartan and candesartan on platelet aggregability and fibrinolysis in type 2 diabetic hypertensive patients. <i>American Journal of Hypertension</i> , 2003, 16, A70.	1.0	0
324	Effect of manidipine-simvastatin combination on fibrinolysis, adhesion molecules and C-reactive protein in hypertensive hypercholesterolemic patients. <i>American Journal of Hypertension</i> , 2005, 18, A171-A171.	1.0	0

#	ARTICLE	IF	CITATIONS
325	We-P11:93 Combining natural treatments to reach lipid target in metabolic syndrome patients: A randomized clinical trial. <i>Atherosclerosis Supplements</i> , 2006, 7, 366.	1.2	0
326	We-P14:482 Efficacy of soluble fiber supplementation in CV disease risk management of patients with metabolic syndrome: A 6-months, randomized clinical trial. <i>Atherosclerosis Supplements</i> , 2006, 7, 453.	1.2	0
327	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 559-569.	0.2	0
328	PO20-625 EFFICACY OF SOLUBLE FIBER SUPPLEMENTATION IN CVD RISK MANAGEMENT OF PATIENTS AFFECTED BY METABOLIC SYNDROME: A 6-MONTHS, OPEN-LABEL, RCT. <i>Atherosclerosis Supplements</i> , 2007, 8, 169.	1.2	0
329	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 0, Volume 2, 51-60.	1.1	0
330	Re: The Influence of Statin Medications on Prostate-Specific Antigen Levels. <i>Journal of the National Cancer Institute</i> , 2009, 101, 610-610.	3.0	0
331	MS2 EFFECTS OF SIBUTRAMINE PLUS L-CARNITINE COMPARED TO SIBUTRAMINE OR PLACEBO ON INFLAMMATORY PARAMETERS. <i>Atherosclerosis Supplements</i> , 2010, 11, 109.	1.2	0
332	Optimizing glycemic control: clinical utility of exenatide prolonged release injection. <i>Research and Reports in Endocrine Disorders</i> , 0, , 41.	0.4	0
333	Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. <i>Hypertension Research</i> , 2014, 37, 492-493.	1.5	0
334	Pharmacotherapy for Obesity. , 2014, , 261-277.		0
335	Safety and efficacy of albiglutide results from two trials. <i>Nature Reviews Endocrinology</i> , 2014, 10, 514-516.	4.3	0
336	6D.07. <i>Journal of Hypertension</i> , 2015, 33, e84.	0.3	0
337	Is it time to implement a standardized oral glucose and fat load test to detect high risk patients? Probably not yet. <i>Atherosclerosis</i> , 2015, 243, 346-347.	0.4	0
338	Possible therapies for obesity: Focus on the available options for its treatment. <i>Nutrition</i> , 2015, 31, 542-543.	1.1	0
339	Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles. , 2016, , 3-26.		0
340	Histological Biomarkers of Nonalcoholic Fatty Liver Disease. <i>Exposure and Health</i> , 2016, , 1-13.	2.8	0
341	[OP.4C.09] COMPARISON BETWEEN CANRENONE OR HYDROCHLOROTHIAZIDE IN ADDITION TO SARTANS IN HYPERTENSIVE DIABETIC PATIENTS. <i>Journal of Hypertension</i> , 2016, 34, e49.	0.3	0
342	P6583 Oral anticoagulants in diabetic and nondiabetic patients with non-valvular atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, .	1.0	0

#	ARTICLE	IF	CITATIONS
343	Effects of sitagliptin on lipid profile in type 2 diabetic patients after seven years of therapy. <i>Atherosclerosis</i> , 2018, 275, e57-e58.	0.4	0
344	Effects Of Pcsk-9 Inhibitors On Lipid Profile: An Italian, Real Life, Multicentric Experience. <i>Atherosclerosis</i> , 2019, 287, e199.	0.4	0
345	Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Treated With Metformin and Sulfonylurea. <i>Journal of the Endocrine Society</i> , 2021, 5, A331-A331.	0.1	0
346	W01.18 Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes. <i>Atherosclerosis</i> , 2004, 5, 5.	0.4	0
347	W01.17 Matrix metalloproteinase 2 and 9 evaluation in patients with or without diabetes during acute coronary syndrome and after the acute event. <i>Atherosclerosis</i> , 2004, 5, 4-5.	0.4	0
348	EFFECT OF MANIDIPINE AND ATENOLOL ON PLATELET AGGREGABILITY IN ISOLATED SYSTOLIC HYPERTENSION WITH AND WITHOUT TYPE 2 DIABETES MELLITUS. <i>Journal of Hypertension</i> , 2004, 22, S224.	0.3	0
349	EFFECT OF AMLODIPINE-ATORVASTATIN COMBINATION ON FIBRINOLYSIS IN HYPERTENSIVE HYPERCHOLESTEROLEMIC INSULIN-RESISTANT PATIENTS. <i>Journal of Hypertension</i> , 2004, 22, S365.	0.3	0
350	EFFECT OF VALSARTAN ON INSULIN SENSITIVITY AND LEPTIN IN HYPERTENSIVE OBESE PATIENTS. <i>Journal of Hypertension</i> , 2004, 22, S90.	0.3	0
351	Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009, 3, 47-54.	0.2	0
352	Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Liver Disease. <i>Biomarkers in Disease</i> , 2017, , 707-717.	0.0	0
353	Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 559-569.	0.2	0
354	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> , 0, , 70-78.	4.0	0